Masamha CP[Author] - Search Results

Year	Number of Results
2009	2
2011	1
2014	1
2016	2
2017	2
2018	5
2019	1
2022	2
2023	2
2024	0

1

The contribution of alternative polyadenylation to the cancer phenotype.

Masamha CP, Wagner EJ. Masamha CP, et al. Carcinogenesis. 2018 Jan 12;39(1):2-10. doi: 10.1093/carcin/bgx096. Carcinogenesis. 2018. PMID: 28968750 Review.

2

The drive to generate multiple forms of oncogenic cyclin D1 transcripts in mantle cell lymphoma.

Masamha CP. Masamha CP. Biomark Res. 2017 May 8;5:16. doi: 10.1186/s40364-017-0094-7. eCollection 2017. Biomark Res. 2017. PMID: 28503306 Free PMC article.

3

The emerging roles of CFIm25 (NUDT21/CPSF5) in human biology and disease.

Masamha CP. Masamha CP. Wiley Interdiscip Rev RNA. 2023 May-Jun;14(3):e1757. doi: 10.1002/wrna.1757. Epub 2022 Aug 14. Wiley Interdiscip Rev RNA. 2023. PMID: 35965101 Free PMC article. Review.

4

Author Correction: CFIm25 links alternative polyadenylation to glioblastoma tumour suppression.

Masamha CP, Xia Z, Yang J, Albrecht TR, Li M, Shyu AB, Li W, Wagner EJ. Masamha CP, et al. Nature. 2022 Dec;612(7940):E11. doi: 10.1038/s41586-022-05459-6. Nature. 2022. PMID: 36418405 No abstract available.

5

The role and impact of alternative polyadenylation and miRNA regulation on the expression of the multidrug resistance-associated protein 1 (MRP-1/ABCC1) in epithelial ovarian cancer.

Marjamaa A, Gibbs B, Kotrba C, Masamha CP. Marjamaa A, et al. Among authors: masamha cp. Sci Rep. 2023 Oct 14;13(1):17476. doi: 10.1038/s41598-023-44548-y. Sci Rep. 2023. PMID: 37838788 Free PMC article.

6

The pro-survival function of Akt kinase can be overridden or altered to contribute to induction of apoptosis.

Benbrook DM, Masamha CP. Benbrook DM, et al. Among authors: masamha cp. Curr Cancer Drug Targets. 2011 Jun;11(5):586-99. doi: 10.2174/156800911795655994. Curr Cancer Drug Targets. 2011. PMID: 21486222 Review.

7

Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy.

Masamha CP, LaFontaine P. Masamha CP, et al. J Cell Biochem. 2018 Jul;119(7):6136-6145. doi: 10.1002/jcb.26814. Epub 2018 Apr 10. J Cell Biochem. 2018. PMID: 29633308

8

Development of flexible-heteroarotinoids for kidney cancer.

Liu T, Masamha CP, Chengedza S, Berlin KD, Lightfoot S, He F, Benbrook DM. Liu T, et al. Among authors: masamha cp. Mol Cancer Ther. 2009 May;8(5):1227-38. doi: 10.1158/1535-7163.MCT-08-1069. Epub 2009 May 5. Mol Cancer Ther. 2009. PMID: 19417155 Free PMC article.

9

Development of a dietary formulation of the SHetA2 chemoprevention drug for mice.

Benbrook DM, Janakiram NB, Chandra V, Pathuri G, Madka V, Stratton NC, Masamha CP, Farnsworth CN, Garcia-Contreras L, Hatipoglu MK, Lighfoot S, Rao CV. Benbrook DM, et al. Among authors: masamha cp. Invest New Drugs. 2018 Aug;36(4):561-570. doi: 10.1007/s10637-017-0550-0. Epub 2017 Dec 22. Invest New Drugs. 2018. PMID: 29273857 Free PMC article.

10

3' UTR shortening represses tumor-suppressor genes in trans by disrupting ceRNA crosstalk.

Park HJ, Ji P, Kim S, Xia Z, Rodriguez B, Li L, Su J, Chen K, Masamha CP, Baillat D, Fontes-Garfias CR, Shyu AB, Neilson JR, Wagner EJ, Li W. Park HJ, et al. Among authors: masamha cp. Nat Genet. 2018 Jun;50(6):783-789. doi: 10.1038/s41588-018-0118-8. Epub 2018 May 21. Nat Genet. 2018. PMID: 29785014 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

16 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year